Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$52.03 USD

52.03
732,290

+0.17 (0.33%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $52.04 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Humana's (HUM) Arm to Aid Senior Care, 2023 Expansion on Track

by Zacks Equity Research

Humana's (HUM) CenterWell brand plans to open centers in untapped markets as well as dig deeper into the existing regions offering enhanced primary care services to the nation's senior citizens.

NuVasive (NUVA) Q3 Earnings Beat Estimates, Guidance Cut

by Zacks Equity Research

The continued demand for NuVasive's (NUVA) Simplified Cervical Disc is encouraging.

Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Cardinal Health's (CAH) Velocare to Enhance at-Home Care

by Zacks Equity Research

Cardinal Health's (CAH) latest launch is expected to significantly expand its at-Home Solutions supply chain and logistics services, thereby improving patient care.

3 Reasons to Retain Abbott (ABT) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business.

AMN vs. DOCS: Which Stock Is the Better Value Option?

by Zacks Equity Research

AMN vs. DOCS: Which Stock Is the Better Value Option?

PerkinElmer's (PKI) New Marketing Approval to Aid Infant Health

by Zacks Equity Research

PerkinElmer's (PKI) EONIS SCID-SMA assay kit is expected to enable early SMA and SCID screening in newborns following the FDA's approval.

Phibro (PAHC) Q1 Earnings Miss Estimates, Sales Surpass

by Zacks Equity Research

Phibro's (PAHC) growing uptake of MFAs, dairy products and vaccines buoys optimism.

What Makes AMN Healthcare (AMN) a Good Fit for "Trend Investing"

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, AMN Healthcare (AMN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Teladoc (TDOC) Achieves Momentous 50M Milestone in Visits

by Zacks Equity Research

Of the 50 million visits to Teladoc (TDOC), around one-third took place in the last year alone.

Patterson Companies' (PDCO) New Buyout to Expand Product Suite

by Zacks Equity Research

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its Animal Health's product offerings.

DENTSPLY SIRONA (XRAY) Q3 Earnings & Revenues Miss Estimates

by Zacks Equity Research

Despite a year-over-year decline in both earnings and revenues, DENTSPLY SIRONA's (XRAY) third-quarter results benefit from the Technologies & Equipment business.

National Vision (EYE) Q3 Earnings Top Mark, Margins Down

by Zacks Equity Research

National Vision (EYE) is facing demand headwinds across its network of stores due to the constraints on eye exam capacity.

Globus Medical (GMED) Q3 Earnings Miss Estimates, EPS View Cut

by Zacks Equity Research

Internationally, Globus Medical (GMED) reports double-digit growth in most markets, with the U.K., Australia, Brazil, India and Poland registering more than 40% growth.

Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment

by Zacks Equity Research

Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Cardiovascular Systems (CSII) Q1 Earnings Miss, Revenues Top

by Zacks Equity Research

The launch of the Scoreflex scoring balloon receives a positive response and generates over $1.7 million in sales during the first quarter for Cardiovascular Systems (CSII).

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Improving margins buoy optimism.

Haemonetics (HAE) Q2 Earnings Beat Estimates, 2023 View Up

by Zacks Equity Research

Under the Hospital segment, despite continued macroeconomic, Haemonetics (HAE) meaningfully grows revenues and market share.

Patterson Companies (PDCO) Inks Deal to Expand Product Suite

by Zacks Equity Research

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its value-add platform.

BD (BDX) Q4 Earnings and Revenues Beat Estimates, Margins Up

by Zacks Equity Research

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal fourth quarter.

QIAGEN's (QGEN) Q3 Earnings Top Estimates, 2022 View Up

by Zacks Equity Research

The ongoing double-digit sales growth in the non-COVID product portfolio, a high level of profitability and strong cash flow are the major upsides for QIAGEN (QGEN).

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

STERIS (STE) Q2 Earnings Miss Estimates, Margins Increase

by Zacks Equity Research

Barring AST, poor reported revenue performance across three of STERIS' (STE) operating segments poses concerns.